Q1 FY27, unaudited
- Revenue
- ₹561.00 Cr
- Profit after tax
- ₹107.00 Cr
As filed with the exchange, standalone basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 561.00 | +35.84% | 1,739.00 |
| Other income | 33.00 | +32.00% | 137.00 |
| Total income | 594.00 | +35.62% | 1,876.00 |
| Employee benefit expense | 85.00 | +25.00% | 313.00 |
| Finance costs | 43.00 | +4.88% | 176.00 |
| Depreciation & amortisation | 41.00 | −10.87% | 186.00 |
| Total expenses | 487.00 | +31.98% | 1,584.00 |
| Profit before tax | 107.00 | +55.07% | 317.00 |
| Tax expense | 0.00 | — | 0.00 |
| Profit after tax | 107.00 | +55.07% | 317.00 |
| Total comprehensive income | 107.00 | +55.07% | 317.00 |
| Earnings per share, basic | ₹6.62 | ₹19.54 |
|---|---|---|
| Earnings per share, diluted | ₹6.61 | ₹19.52 |
Earnings call
Q4 FY26Wockhardt reported FY26 revenue of INR3,373 crores with EBITDA of about INR630 crores, EBITDA growth of 51%, and profit before tax of INR238 crores, while EBITDA margin rose from 5.4% three years ago to 18.6%. Management described Zaynich, its novel antibiotic, receiving US FDA approval as a major milestone and laid out launch plans for the US, India, and emerging markets, alongside growth of 35% in the biosimilar business and 27% growth in the specialty segment. Executives also discussed capex plans, patent life, manufacturing strategy across India and Europe, and commercial partnership structures for the US launch.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Filings
12 shown · 35 published by the exchange
25 Aug 2026
25 Aug 2026
Filing10 Aug 2026
10 Aug 2026
10 Aug 2026
Filing10 Aug 2026
10 Aug 2026
10 Aug 2026
07 Aug 2026
Filing05 Aug 2026
04 Aug 2026
18 Jul 2026
Filing
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 25 Aug 2026.